PODXL and glioblastoma: In SW1783 and U-87 astrocytoma cell lines, PODXL increased cell survival against apoptosis induced by temozolomide, a DNA-alkylating agent widely used as standard therapy for glioblastoma multiforme, through the up-regulation of PI3K/AKT signaling pathway [90].